表皮™ approved by OECD as st和-alone in-vitro test method for phototoxicity

贴在 2021年6月23日 |
类别 im体育app, 毒理学

im体育app稿
瑞典哥德堡
6月23日15:00(美国东部时间)

 

CELLINKs表皮 skin model has been approved by the OECD as a st和-alone in-vitro test method for phototoxicity

im体育app生命科学, CELLINK的子公司, today announced the acceptance of the 表皮™ 光毒性 Test as part of 测试准则没有. 498 In vitro 光毒性: Reconstructed Human Epidermis 光毒性 Test Method by the Organization of Economic Cooperation 和 Development (OECD). This effort is very much in line with the Group’s goals to reduce 和 eventually replace animal testing by developing technologies 和 methods that are more human-relevant 和 provide a more accurate prediction of human clinical responses. This is the fourth OECD test guideline validation for im体育app’s in vitro tissue models following validations for 皮肤刺激(OECD TG 439), 皮肤腐蚀(OECD TG 431) 眼睛刺激(OECD TG 492).

Test Guideline 498 is a st和-alone method for evaluating the phototoxic potential of a test chemical after topical application in reconstructed human epidermis (RhE) in the presence 和 absence of simulated sunlight. 光毒性 potential is evaluated by relative reduction in viability of cells exposed to the test chemical as compared to the absence of simulated sunlight. Chemicals identified as positive in this test have been found to be phototoxic in clinical evaluations following topical application to the skin.

The project included testing of over 60 compounds on im体育app’s 表皮 human epidermal skin tissue model, which is currently the only tissue model accepted under the test guideline. 表皮, 第一部于1993年出品, has been used to test the phototoxic potential of topically applied drugs 和 skincare 产品 since 1997. The phototoxicity protocol was first developed by Dr. Manfred Liebsch of ZEBET 和 refined by Dr. Helena K和arova, who also spearheaded the OECD acceptance effort.

This is a big advancement over accepted guidelines, 比如3T3试验, which uses a mouse fibroblast cell line 和 is highly over predictive which erroneously disqualifies perfectly viable compounds for 个人护理 产品,” said Alex Armento, CEO of im体育app. “This effort is very much in line with our goals to reduce 和 eventually replace animal testing by developing technologies 和 methods that are more human-relevant 和 provide a more accurate prediction of human clinical responses. This new regulatory acceptance is further proof that in vitro tissue models are a better predictive method.”

im体育app产生表皮, along with an expansive catalogue of additional lab-grown human tissues, for shipment to laboratories 和 researchers around the globe, 和 performs in-house testing services for industry clients, making it the most diverse 和 widely available technology of its kind.

For further information, please contact:

首席执行官埃里克Gatenholm
Phone (Sweden): +46 73 267 00 00
电话(美国):+1 (650)515 5566
电子邮件: eg@cellink.com
Gusten Danielsson首席财务官
Phone (Sweden): +46 70 991 86 04
电话(美国):+1 (857)332 2138
电子邮件: gd@cellink.com 

This is information that CELLINK AB (publ) submitted for publication, through the agency of the contact persons set out above, on 2021年6月23日 at 15:00 (CEST).

 

 im体育appCELLINK

成立于2016年, CELLINK is the leading bioconvergence company in the world that provides technologies, 产品, 和服务创造, 理解并掌握生物学. With a focus on the application areas of bioprinting, multiomics, 细胞系的发展, 和诊断, the company develops 和 markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening 和 print human tissues 和 organs for the medical, 制药, 和化妆品行业. CELLINK’s 产品 are trusted by more than 2,000实验室, including all the top 20 制药 companies, are being used in more than 65 countries, 和 have been cited in more than 1,700年的出版物. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com

im体育app

im体育app was founded in 1985 和 began producing human tissue models as reliable replacements for animal testing. im体育app的皮肤, 眼, 口服, 呼吸, 和 intestinal tissue models are used to assess safety 和 efficacy throughout the 制药, 化妆品, 个人护理, 和 household product industries. These advanced tissue models empower companies to achieve their goals of non-animal testing while lowering testing costs 和 providing human-relevant results. The company has exp和ed its offerings to include cultureware, 原代人类细胞和培养基, 3 diy套件, 和 testing services in support of its mission to advance innovative in vitro science through the production of synergistic life science 产品 和 services. www.wnuvradio.com

共享是关怀!